Sali M K Farhan1, Jian Wang2, John F Robinson2, Asuri N Prasad3, C Anthony Rupar4, Victoria M Siu4, Robert A Hegele1. 1. Robarts Research Institute, London, Ontario, Canada Department of Biochemistry, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada. 2. Robarts Research Institute, London, Ontario, Canada. 3. Division of Clinical Neurological Sciences, Department of Pediatrics, London Health Sciences Centre, London, Ontario, Canada Children's Health Research Institute, London, Ontario, Canada. 4. Department of Biochemistry, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada Children's Health Research Institute, London, Ontario, Canada Medical Genetics Program, Department of Pediatrics, London Health Sciences Centre, London, Ontario, Canada.
Abstract
BACKGROUND: Heparan sulfate proteoglycans are vital components of the extracellular matrix and are essential for cellular homeostasis. Many genes are involved in modulating heparan sulfate synthesis, and when these genes are mutated, they can give rise to early-onset developmental disorders affecting multiple body systems. Herein, we describe a consanguineous family of four sibs with a novel disorder, which we designate as seizures-scoliosis-macrocephaly syndrome, characterised by seizures, intellectual disability, hypotonia, scoliosis, macrocephaly, hypertelorism and renal dysfunction. METHODS: Our application of autozygosity mapping and whole-exome sequencing allowed us to identify mutations in the patients. To confirm the autosomal-recessive mode of inheritance, all available family members were genotyped. We also studied the effect of these mutations on protein expression and function in patient cells and using an in vitro system. RESULTS: We identified two homozygous mutations p.Met87Arg and p.Arg95 Cys in exostosin 2, EXT2, a ubiquitously expressed gene that encodes a glycosyltransferase required for heparan sulfate synthesis. In patient cells, we observed diminished EXT2 expression and function. We also performed an in vitro assay to determine which mutation has a larger effect on protein expression and observed reduced EXT2 expression in constructs expressing either one of the mutations but a greater reduction when both residues were mutated. CONCLUSIONS: In short, we have unravelled the genetic basis of a new recessive disorder, seizures-scoliosis-macrocephaly syndrome. Our results have implicated a well-characterised gene in a new developmental disorder and have further illustrated the spectrum of phenotypes that can arise due to errors in glycosylation. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
BACKGROUND:Heparan sulfate proteoglycans are vital components of the extracellular matrix and are essential for cellular homeostasis. Many genes are involved in modulating heparan sulfate synthesis, and when these genes are mutated, they can give rise to early-onset developmental disorders affecting multiple body systems. Herein, we describe a consanguineous family of four sibs with a novel disorder, which we designate as seizures-scoliosis-macrocephaly syndrome, characterised by seizures, intellectual disability, hypotonia, scoliosis, macrocephaly, hypertelorism and renal dysfunction. METHODS: Our application of autozygosity mapping and whole-exome sequencing allowed us to identify mutations in the patients. To confirm the autosomal-recessive mode of inheritance, all available family members were genotyped. We also studied the effect of these mutations on protein expression and function in patient cells and using an in vitro system. RESULTS: We identified two homozygous mutations p.Met87Arg and p.Arg95 Cys in exostosin 2, EXT2, a ubiquitously expressed gene that encodes a glycosyltransferase required for heparan sulfate synthesis. In patient cells, we observed diminished EXT2 expression and function. We also performed an in vitro assay to determine which mutation has a larger effect on protein expression and observed reduced EXT2 expression in constructs expressing either one of the mutations but a greater reduction when both residues were mutated. CONCLUSIONS: In short, we have unravelled the genetic basis of a new recessive disorder, seizures-scoliosis-macrocephaly syndrome. Our results have implicated a well-characterised gene in a new developmental disorder and have further illustrated the spectrum of phenotypes that can arise due to errors in glycosylation. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: Alex R DeCasien; Amber E Trujillo; Mareike C Janiak; Etta P Harshaw; Zosia N Caes; Gabriela A Galindo; Rachel M Petersen; James P Higham Journal: Sci Rep Date: 2022-06-28 Impact factor: 4.996
Authors: Machteld M Oud; Paul Tuijnenburg; Maja Hempel; Naomi van Vlies; Zemin Ren; Sacha Ferdinandusse; Machiel H Jansen; René Santer; Jessika Johannsen; Chiara Bacchelli; Marielle Alders; Rui Li; Rosalind Davies; Lucie Dupuis; Catherine M Cale; Ronald J A Wanders; Steven T Pals; Louise Ocaka; Chela James; Ingo Müller; Kai Lehmberg; Tim Strom; Hartmut Engels; Hywel J Williams; Phil Beales; Ronald Roepman; Patricia Dias; Han G Brunner; Jan-Maarten Cobben; Christine Hall; Taila Hartley; Polona Le Quesne Stabej; Roberto Mendoza-Londono; E Graham Davies; Sérgio B de Sousa; Davor Lessel; Heleen H Arts; Taco W Kuijpers Journal: Am J Hum Genet Date: 2017-01-26 Impact factor: 11.025
Authors: Linda R Wang; Aleksandar Radonjic; Allison A Dilliott; Adam D McIntyre; Robert A Hegele Journal: J Investig Med High Impact Case Rep Date: 2018-07-12
Authors: Sali M K Farhan; Kevin C J Nixon; Michelle Everest; Tara N Edwards; Shirley Long; Dmitri Segal; Maria J Knip; Heleen H Arts; Rana Chakrabarti; Jian Wang; John F Robinson; Donald Lee; Seyed M Mirsattari; C Anthony Rupar; Victoria M Siu; Michael O Poulter; Robert A Hegele; Jamie M Kramer Journal: Hum Mol Genet Date: 2017-11-01 Impact factor: 6.150